
-
Canada wildfire near Vancouver contained
-
Four Atletico ultras get suspended jail for Vinicius effigy
-
England's top women's league to expand to 14 teams
-
Oil prices drop, stocks climb as Iran-Israel war fears ease
-
UN refugee agency says will shed 3,500 jobs due to funding cuts
-
US moves to protect all species of pangolin, world's most trafficked mammal
-
Kneecap 'unfazed' by legal problems, says friend and director
-
Electric fences, drones, dogs protect G7 leaders from bear attack
-
The name's Metreweli... Who is UK MI6's first woman chief?
-
Oil prices fall, stocks rise as Iran-Israel war fears ease
-
Fighter jets, refuelling aircraft, frigate: UK assets in Mideast
-
Iranian Nobel laureates, Cannes winner urge halt to Iran-Israel conflict
-
Struggling Gucci owner's shares soar over new CEO reports
-
Khamenei, Iran's political survivor, faces ultimate test
-
Ireland prepares to excavate 'mass grave' at mother and baby home
-
France shuts Israeli weapons booths at Paris Air Show
-
Iran and Israel exchange deadly strikes in spiralling air war
-
Ex-England captain Farrell rejoins Saracens from Racing 92
-
UN slashes global aid plan over 'deepest funding cuts ever'
-
Sri Lanka's Mathews hails 'dream run' in final Test against Bangladesh
-
Former England captain Farrell rejoins Saracens from Racing 92
-
Olympic champ Ingebrigtsen's father acquitted of abusing son
-
Maria climbs 43 places in WTA rankings after Queen's win
-
Iran hits Israel with deadly missile onslaught
-
German court jails Syrian 'torture' doctor for life
-
Oil prices fall even as Israel-Iran strikes extend into fourth day
-
Scientists track egret's 38-hour flight from Australia to PNG
-
Los Angeles curfew to continue for 'couple more days': mayor
-
Iran hits Tel Aviv after overnight Israeli strikes on Tehran
-
China factory output slows but consumption offers bright spot
-
G7 confronts Israel-Iran crisis as Trump dominates summit
-
Relatives wait for remains after Air India crash
-
China factory output slumps but consumption offers bright spot
-
Record-breaking Japan striker 'King Kazu' plays at 58
-
Trump lands in Canada as G7 confronts Israel-Iran crisis
-
Oil prices rise further as Israel-Iran extends into fourth day
-
Olympic champ Ingebrigtsen's father set for abuse trial verdict
-
German court to rule in case of Syrian 'torture' doctor
-
Trump orders deportation drive targeting Democratic cities
-
Spaun creates his magic moment to win first major at US Open
-
Royal Ascot battling 'headwinds' to secure foreign aces: racing director
-
Spaun wins US Open for first major title with late birdie binge
-
Israel pounds Iran, Tehran hits back with missiles
-
'Thin' chance against Chelsea but nothing to lose: LAFC's Lloris
-
PSG cruise over Atletico, Bayern thrash Auckland at Club World Cup
-
G7 protests hit Calgary with leaders far away
-
USA end losing streak with crushing of hapless Trinidad
-
UK appoints Blaise Metreweli first woman head of MI6 spy service
-
One dead after 6.1-magnitude earthquake in Peru
-
GA-ASI Adds Saab Airborne Early Warning Capability to MQ-9B

Moderna Covid vaccine gets full US approval
The US Food and Drug Administration (FDA) announced Monday that it has granted full approval to Moderna's Covid-19 "Spikevax" vaccine, which had previously received an emergency use authorization in the United States.
"The public can be assured that Spikevax meets the FDA's high standards for safety, effectiveness and manufacturing quality required of any vaccine approved for use in the United States," acting FDA commissioner Janet Woodcock said in a statement.
"The FDA's approval of Spikevax is a significant step in the fight against the Covid-19 pandemic, marking the second vaccine approved to prevent Covid-19," Woodcock said.
The full approval of the Moderna vaccine is for individuals aged 18 or older.
A Pfizer vaccine for individuals aged 16 or older received full FDA approval at the end of August.
Woodcock said she hoped FDA approval of the Moderna vaccine "may instill additional confidence in making the decision to get vaccinated."
Moderna CEO Stephane Bancel called the FDA move a "momentous milestone" for the company.
"Our Covid-19 vaccine has been administered to hundreds of millions of people around the world, protecting people from Covid-19 infection, hospitalization and death," Bancel said in a statement.
The Moderna vaccine received an emergency use authorization in December 2020.
The full approval from the FDA concerns the first two doses of the Moderna vaccine. A booster dose remains under an emergency use authorization.
The FDA said clinical trials to determine the effectiveness of Spikevax included 14,287 vaccine recipients and 14,164 placebo recipients.
The most common side effects by clinical trial participants were pain at the injection site, fatigue, headaches, muscle or joint pain, chills, nausea or vomiting and swollen lymph nodes, the FDA said.
It said there was an increased risk in men aged 18 to 24 of myocarditis -- inflammation of the heart muscle -- and pericarditis -- inflammation of tissue surrounding the heart -- following vaccination with the second dose.
But, the FDA said, it has determined that the "benefits of the vaccine outweigh the risk of myocarditis and pericarditis in individuals 18 years of age and older."
V.Said--SF-PST